Match!

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Published on Sep 1, 2016in Nature43.07
· DOI :10.1038/nature19323
Jeff Sevigny4
Estimated H-index: 4
,
Ping Chiao7
Estimated H-index: 7
+ 25 AuthorsAlfred Sandrock25
Estimated H-index: 25
Sources
Abstract
Aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ, reduces soluble and insoluble Aβ in the brain, an action accompanied by a dose-dependent slowing of clinical decline in treated patients.
  • References (40)
  • Citations (632)
📖 Papers frequently viewed together
3,204 Citations
895 Citations
819 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References40
Newest
#1James Ferrero (Biogen Idec)H-Index: 3
#2Leslie Williams (Biogen Idec)H-Index: 5
Last. Jeff Sevigny (Biogen Idec)H-Index: 4
view all 7 authors...
Abstract Introduction Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta, is being investigated as a disease-modifying treatment for Alzheimer's disease (AD). Methods This randomized, double-blind, placebo-controlled single ascending-dose study investigated the safety, tolerability, and pharmacokinetics (PK) of aducanumab in patients with mild-to-moderate AD. Eligible patients were sequentially randomized 6:2 to aducanumab (0.3, 1, 3, 10, 20, 30, and...
11 CitationsSource
#1Heledd H. Jarosz-Griffiths (University of Manchester)H-Index: 2
#2Elizabeth Noble (University of Manchester)H-Index: 1
Last. Nigel M. Hooper (University of Manchester)H-Index: 62
view all 4 authors...
Several different receptor proteins have been identified that bind monomeric, oligomeric, or fibrillar forms of amyloid-β (Aβ). “Good” receptors internalize Aβ or promote its transcytosis out of the brain, whereas “bad” receptors bind oligomeric forms of Aβ that are largely responsible for the synapticloss, memory impairments, and neurotoxicity that underlie Alzheimer disease. The prion protein both removes Aβ from the brain and transduces the toxic actions of Aβ. The clustering of distinct rece...
79 CitationsSource
#1Jeff SevignyH-Index: 4
#2Joyce SuhyH-Index: 17
Last. Jerome BarakosH-Index: 17
view all 10 authors...
Amyloid positron emission tomography (PET) imaging is being investigated as a screening tool to identify amyloid-positive patients as an enrichment strategy for Alzheimer disease (AD) clinical trial enrollment. In a multicenter, phase 1b trial, patients meeting clinical criteria for prodromal or mild AD underwent florbetapir PET scanning at screening. PET, magnetic resonance imaging, and coregistered PET/magnetic resonance imaging scans were reviewed by 2 independent readers and binary visual re...
32 CitationsSource
#1C Ising (WashU: Washington University in St. Louis)H-Index: 1
#2M Stanley (WashU: Washington University in St. Louis)H-Index: 1
Last. David M. Holtzman (WashU: Washington University in St. Louis)H-Index: 136
view all 3 authors...
Alzheimer disease (AD) is the most common cause of dementia and is characterized by the aggregation and accumulation of two proteins in the brain, amyloid-β (Aβ) and tau. Aβ and tau begin to buildup 15-20 years before the clinical onset of AD dementia. Increasing evidence suggests that preventing or decreasing the amount of aggregated forms of both Aβ and tau in the brain can serve as potential disease-modifying treatments for AD.
32 CitationsSource
Although it is well documented that soluble beta amyloid (Aβ) oligomers are critical factors in the pathogenesis of Alzheimer's disease (AD) by causing synaptic dysfunction and neuronal death, the primary mechanisms by which Aβ oligomers trigger neurodegeneration are not entirely understood. We sought to investigate whether toxic small Aβ1–42 oligomers induce changes in plasma membrane potential of cultured neurons and glial cells in rat cerebellar granule cell cultures leading to neuronal death...
13 CitationsSource
#1Carlo Condello (Yale University)H-Index: 14
#2Peng Yuan (Yale University)H-Index: 13
Last. Jaime Grutzendler (Yale University)H-Index: 28
view all 4 authors...
In Alzheimer’s disease (AD), b-amyloid (Ab) plaques are tightly enveloped by microglia processes, but the significance of this phenomenon is unknown. Here we show that microglia constitute a barrier with profound impact on plaque composition and toxicity. Using highresolution confocal and in vivo two-photon imaging in AD mouse models, we demonstrate that this barrier prevents outward plaque expansion and leads to compact plaque microregions with low Ab42 affinity. Areas uncovered by microglia ar...
122 CitationsSource
#1Jeffrey L. Cummings (Cleveland Clinic)H-Index: 135
#2Travis Morstorf (Touro University Nevada)H-Index: 2
Last. Kate Zhong (Cleveland Clinic)H-Index: 13
view all 3 authors...
Introduction Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD.
598 CitationsSource
#1Rachelle S. Doody (BCM: Baylor College of Medicine)H-Index: 60
#2Ronald G. Thomas (UCSD: University of California, San Diego)H-Index: 53
Last. Richard C. Mohs (UCSD: University of California, San Diego)H-Index: 66
view all 13 authors...
BackgroundAlzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. MethodsIn two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively, with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (admin...
819 CitationsSource
#1Stephen Salloway (Brown University)H-Index: 55
#2Reisa A. Sperling (Harvard University)H-Index: 90
Last. H. Robert Brashear (Janssen Pharmaceutica)H-Index: 15
view all 24 authors...
Background Bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease. Methods We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease — one involving 1121 carriers of the apolipoprotein E (APOE) e4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion ...
895 CitationsSource
#1Wagner Zago (Janssen Pharmaceutica)H-Index: 2
#2Sally Schroeter (Janssen Pharmaceutica)H-Index: 1
Last. Gene G. Kinney (Janssen Pharmaceutica)H-Index: 30
view all 11 authors...
Abstract Background Clinical studies of β-amyloid (Aβ) immunotherapy in Alzheimer's disease (AD) patients have demonstrated reduction of central Aβ plaque by positron emission tomography (PET) imaging and the appearance of amyloid-related imaging abnormalities (ARIA). To better understand the relationship between ARIA and the pathophysiology of AD, we undertook a series of studies in PDAPP mice evaluating vascular alterations in the context of central Aβ pathology and after anti-Aβ immunotherapy...
34 CitationsSource
Cited By632
Newest
Source
#1Owen A. Williams (University of Oxford)
#2Yang An (NIH: National Institutes of Health)H-Index: 31
Last. Susan M. Resnick (NIH: National Institutes of Health)H-Index: 72
view all 6 authors...
BACKGROUND: Alzheimer's disease (AD) is now understood to have a long preclinical phase in which pathology starts to accumulate in the absence of clinical symptoms. Identifying the temporal stages of accelerated cognitive decline in this phase may help in developing more sensitive neuropsychological tools for early screening of preclinical cognitive decline. Change-point analyses are increasingly used to characterize the temporal stages of accelerated cognitive decline in the preclinical stages ...
Source
#1Anna-Sophia Wahl (ETH Zurich)H-Index: 5
#2Daphne Correa (ETH Zurich)
Last. Martin E. Schwab (ETH Zurich)H-Index: 99
view all 7 authors...
Antibody-based therapeutics targeting CNS antigens emerge as promising treatments in neurology. However, access to the CNS is limited by the blood-brain barrier. We examined the effects of a neurite growth-enhancing anti-Nogo A antibody therapy following 3 routes of administration-intrathecal (i.t.), intravenous (i.v.), and subcutaneous (s.c.)-after large photothrombotic strokes in adult rats. Intrathecal treatment of full-length IgG anti-Nogo A antibodies enhanced recovery of the grasping funct...
Source
#1Raza QaziH-Index: 4
#2Joo Yong SimH-Index: 11
view all 4 authors...
Source
#1Lawren VandeVrede (UCSF: University of California, San Francisco)H-Index: 6
#2Adam L. Boxer (UCSF: University of California, San Francisco)H-Index: 49
Last. Manuela PolydoroH-Index: 9
view all 3 authors...
Abstract Tauopathies are a group of over 20 clinicopathological neurodegenerative diseases including Alzheimer's disease (AD), the most common type of dementia, progressive supranuclear palsy, Pick's disease, corticobasal degeneration, and Frontotemporal dementia (FTD). Tauopathies are defined by neurodegeneration and the presence of tau aggregates in affected brains regions. Interestingly, regional tau aggregation burden correlates with clinical phenotype and predicts cognitive status. Autosoma...
Source
Source
Source
Source
#1Md. Sahab Uddin (SEU: Southeast University)H-Index: 9
#2Md. Tanvir Kabir (BRACU: BRAC University)H-Index: 4
Last. Mohamed M. Abdel-Daim (KSU: King Saud University)H-Index: 24
view all 9 authors...
Alzheimer’s disease (AD) is the most common cause of dementia among older people, and the prevalence of this disease is estimated to rise quickly in the upcoming years. Unfortunately, almost all of the drug candidates tested for AD until now have failed to exhibit any efficacy. Henceforth, there is an increased necessity to avert and/or slow down the advancement of AD. It is known that one of the major pathological characteristics of AD is the presence of senile plaques (SPs) in the brain. These...
1 CitationsSource
#1Somin Kwon (NIH: National Institutes of Health)H-Index: 1
#2Michiyo Iba (NIH: National Institutes of Health)H-Index: 1
Last. Eliezer Masliah (NIH: National Institutes of Health)H-Index: 148
view all 4 authors...
Neurological disorders such as Alzheimer's disease (AD), Lewy body dementia (LBD), frontotemporal dementia (FTD), and vascular dementia (VCID) have no disease-modifying treatments to date and now constitute a dementia crisis that affects 5 million in the USA and over 50 million worldwide. The most common pathological hallmark of these age-related neurodegenerative diseases is the accumulation of specific proteins, including amyloid beta (Abeta), tau, alpha-synuclein (alpha-syn), TAR DNA-binding ...
Source